Q3 FY2026 · ended May 31, 2026 · Revenue $0 · Filed Jun 24, 2026
Cnbx Pharmaceuticals Inc. (CNBX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended May 31, 2026, it reported revenue of $0 and a net loss of $154,165. As of May 31, 2026 it held $9,487 in cash and investments and $120,000 in total debt.
Revenue
$0
Net income
$-154,165
-158.1% vs year-ago quarter
Operating cash flow
$-47,667
+8.4% vs year-ago quarter
Free cash flow
—
EPS
$0.00
Dividend per share
None
Shares outstanding
1.61B
+1635.8% vs year-ago quarter
Net cash
$-110,513
Q3 FY2026
Operating margin
-508.0%
Q2 FY2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CNBX (OTC)
- Fiscal year ends
- August 31
- Incorporated in
- NV
- Headquarters
- Bethesda, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1343009
- Former names
- Cannabics Pharmaceuticals Inc. (until Mar 16, 2022); American Mining Corp (until May 1, 2014); Thrust Energy Corp. (until May 10, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 May 31, 2026 |
Q2 FY2026 Feb 28, 2026 |
Q1 FY2026 Nov 30, 2025 |
Q4 FY2025 Aug 31, 2025 |
Q3 FY2025 May 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$162,763 | -$72,963 | -$64,002 | -$129,731 | -$40,380 |
| Net income | -$154,165 | -$44,098 | -$113,719 | -$150,109 | -$59,727 |
| Diluted EPS | $0.00 | $0.00 | $0.00 | -$0.00 | $0.00 |
| Operating cash flow | -$47,667 | -$30,549 | -$47,408 | -$28,545 | -$52,019 |
| Total assets | $12,795 | $14,899 | $11,162 | $18,437 | $18,615 |
| Stockholders' equity | -$2.7M | -$2.5M | -$2.6M | -$2.5M | -$2.5M |
| Cash and investments | $9,487 | $12,154 | $7,703 | $15,111 | $13,648 |
| Total debt | $120,000 | $75,000 | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Auditor change
|
Oct 1, 2026 | Sep 28, 2026 |
| 10-Q | Quarterly report | Jun 24, 2026 | May 31, 2026 |
| 10-Q | Quarterly report | Apr 14, 2026 | Feb 28, 2026 |
| 8-K |
Current report
Material agreement
|
Mar 17, 2026 | Mar 10, 2026 |
| 10-Q | Quarterly report | Jan 14, 2026 | Nov 30, 2025 |
| 10-K | Annual report | Dec 1, 2025 | Aug 31, 2025 |
All 301 Cnbx Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.